• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

终末期肝病模型、终末期肝病-钠模型以及Child-Turcotte-Pugh评分随时间变化对肝硬化并发症的预测情况

Model for end-stage liver disease, model for end-stage liver disease-sodium and Child-Turcotte-Pugh scores over time for the prediction of complications of liver cirrhosis.

作者信息

Choi Pil Cho, Kim Hong Joo, Choi Woo Hyuk, Park Dong Il, Park Jung Ho, Cho Yong Kyun, Sohn Chong Il, Jeon Woo Kyu, Kim Byung Ik

机构信息

Department of Emergency Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, Korea.

出版信息

Liver Int. 2009 Feb;29(2):221-6. doi: 10.1111/j.1478-3231.2008.01803.x. Epub 2008 Jun 9.

DOI:10.1111/j.1478-3231.2008.01803.x
PMID:18544124
Abstract

BACKGROUND/AIMS: There has been no report concerning the predictive capability of each scoring system in determining the development of complications of liver cirrhosis such as variceal bleeding and/or hepatic encephalopathy.

METHODS

We retrospectively studied 128 patients with liver cirrhosis [92 males; mean (standard deviation) 54.2 (11.2) years] admitted to our institution from March 2004 to April 2006. Seventy-three patients (57.0%, group 1) were admitted because of complications of cirrhosis and 55 patients (43.0%, group 2) were admitted for causes unrelated to complications of cirrhosis. We calculated values for model for end-stage liver disease (MELD), MELD-sodium (MELD-Na) and Child-Turcotte-Pugh (CTP) scores on admission and at 3 and 6 months before admission. Each delta score was defined as the difference in the scores of 3 and 6 months before admission.

RESULTS

The relative risk for complications in the patients with DeltaMELD/3 months >/=1.35, DeltaMELD-Na/3 months >/=1.35 and DeltaCTP/3 months >/=1 was 2.05 [95% confidence intervals (CI) 1.47-2.85, P<0.01], 2.04 (95% CI 1.45-2.88, P<0.01) and 1.98 (95% CI 1.39-2.81, P<0.01) respectively. The area under the receiver-operating characteristic curves of DeltaMELD/3 months, DeltaMELD-Na/3 months and DeltaCTP/3 months for the occurrence of cirrhotic complications were 0.691, 0.694 and 0.722 respectively. A higher DeltaMELD/3 months (>/=1.35), DeltaMELD-Na/3 months (>/=1.35) and DeltaCTP/3 months (>/=1) was associated with decreased survival.

CONCLUSIONS

Delta model for end-stage liver disease/3 months, DeltaMELD-Na/3 months and DeltaCTP/3 months were clinically useful parameters for predicting the occurrence of cirrhotic complications.

摘要

背景/目的:关于每种评分系统在确定肝硬化并发症(如静脉曲张出血和/或肝性脑病)发生方面的预测能力,尚无相关报道。

方法

我们回顾性研究了2004年3月至2006年4月期间入住我院的128例肝硬化患者[92例男性;平均(标准差)年龄54.2(11.2)岁]。73例患者(57.0%,第1组)因肝硬化并发症入院,55例患者(43.0%,第2组)因与肝硬化并发症无关的原因入院。我们计算了入院时以及入院前3个月和6个月时的终末期肝病模型(MELD)、MELD-钠(MELD-Na)和Child-Turcotte-Pugh(CTP)评分值。每个差值评分定义为入院前3个月和6个月评分的差值。

结果

DeltaMELD/3个月≥1.35、DeltaMELD-Na/3个月≥1.35和DeltaCTP/3个月≥1的患者发生并发症的相对风险分别为2.05[95%置信区间(CI)1.47-2.85,P<0.01]、2.04(95%CI 1.45-2.88,P<0.01)和1.98(95%CI 1.39-2.81,P<0.01)。DeltaMELD/3个月、DeltaMELD-Na/3个月和DeltaCTP/3个月预测肝硬化并发症发生的受试者工作特征曲线下面积分别为0.691、0.694和0.722。较高的DeltaMELD/3个月(≥1.35)、DeltaMELD-Na/3个月(≥1.35)和DeltaCTP/3个月(≥1)与生存率降低相关。

结论

终末期肝病模型/3个月差值、DeltaMELD-Na/3个月差值和DeltaCTP/3个月差值是预测肝硬化并发症发生的临床有用参数。

相似文献

1
Model for end-stage liver disease, model for end-stage liver disease-sodium and Child-Turcotte-Pugh scores over time for the prediction of complications of liver cirrhosis.终末期肝病模型、终末期肝病-钠模型以及Child-Turcotte-Pugh评分随时间变化对肝硬化并发症的预测情况
Liver Int. 2009 Feb;29(2):221-6. doi: 10.1111/j.1478-3231.2008.01803.x. Epub 2008 Jun 9.
2
[Usefulness of DeltaMELD/month for prediction of the mortality in the first episode of variceal bleeding patients with liver cirrhosis: comparison with CTP, MELD score and DeltaCTP/month].DeltaMELD/月对肝硬化静脉曲张出血患者首次出血死亡率预测的价值:与CTP、MELD评分及DeltaCTP/月的比较
Korean J Hepatol. 2007 Mar;13(1):51-60.
3
Evaluation of the increase in model for end-stage liver disease (DeltaMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score.终末期肝病模型(DeltaMELD)评分随时间增加作为晚期肝硬化患者预后预测指标的评估:危险因素分析及与初始MELD和Child-Turcotte-Pugh评分的比较
J Hepatol. 2005 Jun;42(6):826-32. doi: 10.1016/j.jhep.2005.01.019. Epub 2005 Mar 31.
4
Model for end-stage liver disease-sodium predicts prognosis in patients with chronic severe hepatitis B.终末期肝病-钠模型可预测慢性重型乙型肝炎患者的预后。
Chin Med J (Engl). 2008 Oct 20;121(20):2065-9.
5
Validation of model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor in patients with cirrhosis.终末期肝病评分与血清钠比值指数模型作为肝硬化患者预后预测指标的验证
J Gastroenterol Hepatol. 2009 Sep;24(9):1547-53. doi: 10.1111/j.1440-1746.2009.05913.x. Epub 2009 Aug 3.
6
Correlation and comparison of the model for end-stage liver disease, portal pressure, and serum sodium for outcome prediction in patients with liver cirrhosis.终末期肝病模型、门静脉压力和血清钠在肝硬化患者预后预测中的相关性及比较
J Clin Gastroenterol. 2007 Aug;41(7):706-12. doi: 10.1097/MCG.0b013e31802dabb3.
7
[Clinical usefulness of DeltaMELD to predict the survival of patients with liver cirrhosis].DeltaMELD对预测肝硬化患者生存率的临床实用性
Korean J Hepatol. 2006 Dec;12(4):530-8.
8
Proposal of a modified Child-Turcotte-Pugh scoring system and comparison with the model for end-stage liver disease for outcome prediction in patients with cirrhosis.改良Child-Turcotte-Pugh评分系统的提议及其与终末期肝病模型在肝硬化患者预后预测方面的比较
Liver Transpl. 2006 Jan;12(1):65-71. doi: 10.1002/lt.20560.
9
Comparison of four model for end-stage liver disease-based prognostic systems for cirrhosis.四种基于终末期肝病模型的肝硬化预后系统比较。
Liver Transpl. 2008 Jun;14(6):837-44. doi: 10.1002/lt.21439.
10
Can inclusion of serum creatinine values improve the Child-Turcotte-Pugh score and challenge the prognostic yield of the model for end-stage liver disease score in the short-term prognostic assessment of cirrhotic patients?纳入血清肌酐值能否改善Child-Turcotte-Pugh评分,并在肝硬化患者的短期预后评估中对终末期肝病模型评分的预后价值提出挑战?
Liver Int. 2004 Oct;24(5):465-70. doi: 10.1111/j.1478-3231.2004.0949.x.

引用本文的文献

1
Construction of a novel prognostic scoring model for HBV-ACLF liver failure based on dynamic data.基于动态数据构建新型 HBV-ACLF 肝衰竭预后评分模型。
Sci Rep. 2024 Jul 2;14(1):15198. doi: 10.1038/s41598-024-63900-4.
2
Child-Pugh Versus MELD Score for the Assessment of Prognosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis of Observational Studies.用于评估肝硬化预后的Child-Pugh评分与终末期肝病模型(MELD)评分:观察性研究的系统评价和荟萃分析
Medicine (Baltimore). 2016 Feb;95(8):e2877. doi: 10.1097/MD.0000000000002877.
3
Comparison of five models for end-stage liver disease in predicting the survival rate of patients with advanced hepatocellular carcinoma.
终末期肝病的五种模型对晚期肝细胞癌患者生存率预测的比较。
Tumour Biol. 2016 Apr;37(4):5265-73. doi: 10.1007/s13277-015-4366-2. Epub 2015 Nov 11.
4
REpeated AutoLogous Infusions of STem cells In Cirrhosis (REALISTIC): a multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of granulocyte colony-stimulating factor (GCSF) mobilised CD133+ bone marrow stem cells in patients with cirrhosis. A study protocol for a randomised controlled trial.肝硬化患者重复自体干细胞输注(REALISTIC):一项多中心、II期、开放标签、随机对照试验,对肝硬化患者重复自体输注粒细胞集落刺激因子(GCSF)动员的CD133 +骨髓干细胞。一项随机对照试验的研究方案。
BMJ Open. 2015 Mar 20;5(3):e007700. doi: 10.1136/bmjopen-2015-007700.
5
The evolution in the prioritization for liver transplantation.肝移植优先级的演变。
Ann Gastroenterol. 2012;25(1):6-13.
6
Clinical significance of perihepatic lymphadenopathy in patients with chronic hepatitis C infection.慢性丙型肝炎感染患者肝周淋巴结病的临床意义。
Dig Dis Sci. 2011 Jul;56(7):2137-44. doi: 10.1007/s10620-010-1555-0. Epub 2011 Jan 23.
7
Prioritization for liver transplantation.肝移植的优先排序。
Nat Rev Gastroenterol Hepatol. 2010 Dec;7(12):659-68. doi: 10.1038/nrgastro.2010.169. Epub 2010 Nov 2.
8
Predictors of minimal hepatic encephalopathy in patients with cirrhosis.肝硬化患者轻微肝性脑病的预测因素。
Saudi J Gastroenterol. 2010 Jul-Sep;16(3):181-7. doi: 10.4103/1319-3767.65189.